Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
3.240
+0.105 (3.35%)
Jun 18, 2025, 4:00 PM - Market closed
Lipocine Revenue
Lipocine had revenue of $93.86K in the quarter ending March 31, 2025, a decrease of -98.77%. This brings the company's revenue in the last twelve months to $3.67M, down -22.00% year-over-year. In the year 2024, Lipocine had annual revenue of $11.20M, down -492.80%.
Revenue (ttm)
$3.67M
Revenue Growth
-22.00%
P/S Ratio
4.66
Revenue / Employee
$229,677
Employees
16
Market Cap
17.15M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LPCN News
- 10 days ago - Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PRNewsWire
- 4 weeks ago - Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - PRNewsWire
- 5 weeks ago - Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - PRNewsWire
- 6 weeks ago - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - PRNewsWire
- 6 weeks ago - Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - PRNewsWire
- 3 months ago - Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - PRNewsWire
- 3 months ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - PRNewsWire
- 3 months ago - Lipocine Announces FDA Labeling Changes for Testosterone Products - PRNewsWire